drugset / Trial / NCT01181063

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

NCT01181063

Phase 1 Completed 20 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

Due to the complexity of orally inhaled products (combination of a formulation and a device)and the topical nature of drug delivery to the lung for efficacy in vitro-in vivo correlation(IVIVC) for inhaled dosage forms is not generally known. The rationale of this pilot study is to gain in vivo data of the Budesonide/formoterol EH product variants under development and compare pulmonary deposition (administration with charcoal) of different product variants of Budesonide/formoterol EH with Symbicort TH.

Timeline

Start
2010-08
Primary completion
2010-10
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 320 ug Inhaled
Subject Budesonide Small molecule 400 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled

Indications